William B. Feldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William B. Feldman has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
Aaron S. Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
25 shared publications- Aaron Seth Kesselheim
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
14 shared publications Jerry Avorn
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
9 shared publicationsS. Sean Tu
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, USA
6 shared publicationsBenjamin N. Rome
Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
4 shared publicationsReed F. Beall
Affiliations Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada
4 shared publications
Latest Publications
- 10 September 2026
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (9) , 1441-1446
Pharmaceutical products with device-only patents: a cross-sectional analysis
- 10 September 2026
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (9) , 1441-1446
Pharmaceutical products with device-only patents: a cross-sectional analysis
- Open Access
Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial
Objective: To compare the risk of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) among new users of azithromycin versus roflumilast in a population of patients with active COPD treated in routine clinical practice. Design: Target trial emulation. Data source: Optum Clinformatics Data Mart Database from 1 March 2011 to 31 August 2024. Participants: Patients aged > 40 years with active COPD and at least 183 days of continuous insurance enrolment who initiated a new oral prescription for maintenance azithromycin or roflumilast. Those with evidence of other pulmonary conditions or alternative indications for azithromycin were excluded. Propensity score matching was used between treatment groups. Main outcome measures: The primary outcome was time to first moderate or severe COPD exacerbation. Cox proportional hazards models estimated hazard ratios. Results: A total of 7550 matched pairs of patients initiating azithromycin versus roflumilast were included in the cohort. The mean age of patients was 70 years, and 56% were women. The unadjusted incidence of a first moderate or severe COPD exacerbation among patients in the cohort receiving azithromycin or roflumilast was 1.2 per person year. Compared with roflumilast, azithromycin was associated with a 17% reduction in the hazard of first moderate or severe COPD exacerbation (hazard ratio 0.83, 95% confidence interval (CI) 0.79 to 0.87; number needed to treat 15, 95% CI 12 to 21). These results were robust across a range of prespecified sensitivity and subgroup analyses. Conclusions: Among patients with active COPD, azithromycin use was associated with a reduced likelihood of moderate or severe COPD exacerbations compared with roflumilast use. Although this study did not assess the comparative safety of these agents, it provides evidence on treatment outcomes that may complement forthcoming data from a large randomised controlled trial. Study registration: Centre for Open Science Real-World Evidence Registry https://osf.io/95d2v .
Open AccessComparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial
Objective: To compare the risk of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) among new users of azithromycin versus roflumilast in a population of patients with active COPD treated in routine clinical practice. Design: Target trial emulation. Data source: Optum Clinformatics Data Mart Database from 1 March 2011 to 31 August 2024. Participants: Patients aged > 40 years with active COPD and at least 183 days of continuous insurance enrolment who initiated a new oral prescription for maintenance azithromycin or roflumilast. Those with evidence of other pulmonary conditions or alternative indications for azithromycin were excluded. Propensity score matching was used between treatment groups. Main outcome measures: The primary outcome was time to first moderate or severe COPD exacerbation. Cox proportional hazards models estimated hazard ratios. Results: A total of 7550 matched pairs of patients initiating azithromycin versus roflumilast were included in the cohort. The mean age of patients was 70 years, and 56% were women. The unadjusted incidence of a first moderate or severe COPD exacerbation among patients in the cohort receiving azithromycin or roflumilast was 1.2 per person year. Compared with roflumilast, azithromycin was associated with a 17% reduction in the hazard of first moderate or severe COPD exacerbation (hazard ratio 0.83, 95% confidence interval (CI) 0.79 to 0.87; number needed to treat 15, 95% CI 12 to 21). These results were robust across a range of prespecified sensitivity and subgroup analyses. Conclusions: Among patients with active COPD, azithromycin use was associated with a reduced likelihood of moderate or severe COPD exacerbations compared with roflumilast use. Although this study did not assess the comparative safety of these agents, it provides evidence on treatment outcomes that may complement forthcoming data from a large randomised controlled trial. Study registration: Centre for Open Science Real-World Evidence Registry https://osf.io/95d2v .
- Open Access
- 3 July 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (7) , qxag154
Ten high-priority areas for health policy research in 2026-2027
Health policy is undergoing a period of rapid transformation, driven by major health reforms, changing market structures, pharmaceutical policy developments, technological innovation, and evolving models of care delivery. These changes have profound implications for health care access, affordability, quality, and health system sustainability. In this editorial, we identify 10 priority areas for health services and policy research that we believe will shape policy debates and evidence needs in the coming years. These priorities are organized across 5 domains: health care access, coverage, quality and delivery system reform; corporatization and financialization of health care systems; pharmaceutical policy and health services research; international comparisons and cross-national learning; and innovation, technological advancements, and resiliency of health systems. Specific areas we discuss include the effects of the H.R.1 on Medicaid coverage and economic security; the future of Medicare Advantage; the impact of immigration policies on access; the consequences of increasing corporatization of health care; reforms to pharmaceutical pricing; the role of international comparative research; and the implications of precision nutrition, climate-related disruptions, and artificial intelligence for health policy and health system performance. Across these topics, we emphasize the need for rigorous, policy-relevant research that moves beyond descriptive analyses to evaluate mechanisms, implementation, and real-world impacts.
- 3 July 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (7) , qxag154
Open AccessTen high-priority areas for health policy research in 2026-2027
Health policy is undergoing a period of rapid transformation, driven by major health reforms, changing market structures, pharmaceutical policy developments, technological innovation, and evolving models of care delivery. These changes have profound implications for health care access, affordability, quality, and health system sustainability. In this editorial, we identify 10 priority areas for health services and policy research that we believe will shape policy debates and evidence needs in the coming years. These priorities are organized across 5 domains: health care access, coverage, quality and delivery system reform; corporatization and financialization of health care systems; pharmaceutical policy and health services research; international comparisons and cross-national learning; and innovation, technological advancements, and resiliency of health systems. Specific areas we discuss include the effects of the H.R.1 on Medicaid coverage and economic security; the future of Medicare Advantage; the impact of immigration policies on access; the consequences of increasing corporatization of health care; reforms to pharmaceutical pricing; the role of international comparative research; and the implications of precision nutrition, climate-related disruptions, and artificial intelligence for health policy and health system performance. Across these topics, we emphasize the need for rigorous, policy-relevant research that moves beyond descriptive analyses to evaluate mechanisms, implementation, and real-world impacts.
- 25 March 2026
- Published by Elsevier in The Joint Commission Journal on Quality and Patient Safety
- Vol. 52 (5-6) , 249-252
Healthcare Ethics Is a Key Underrecognized Step on the Road to High Reliability
- 25 March 2026
- Published by Elsevier in The Joint Commission Journal on Quality and Patient Safety
- Vol. 52 (5-6) , 249-252
Healthcare Ethics Is a Key Underrecognized Step on the Road to High Reliability
- Open Access
- 2 March 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (3) , e260959
Fluticasone- vs Budesonide-Based Dual Therapy for COPD
Importance: Inhaled corticosteroid (ICS)–long-acting β-agonist (LABA) inhalers are generally considered therapeutically equivalent when treating chronic obstructive pulmonary disease (COPD). However, metered-dose inhalers in the class are associated with substantially higher greenhouse gas emissions than dry powder formulations, and studies have raised questions about potential intraclass differences in clinical outcomes among patients receiving ICS-LABAs. Objective: To analyze COPD exacerbations and pneumonia hospitalizations associated with once-daily fluticasone furoate–vilanterol dry powder inhalers, twice-daily fluticasone propionate–salmeterol dry powder inhalers, and twice-daily budesonide-formoterol metered-dose inhalers in adults with COPD. Design, Setting, and Participants: This cohort study was conducted using longitudinal commercial claims data of US adults aged 40 years or older with COPD. Patients were 1:1 pairwise propensity score matched into 3 cohorts: (1) new users receiving fluticasone furoate–vilanterol vs budesonide-formoterol between January 1, 2014, and February 29, 2024; (2) new users receiving fluticasone furoate–vilanterol vs fluticasone propionate–salmeterol between January 1, 2014, and February 29, 2024; and (3) new users receiving fluticasone propionate–salmeterol vs budesonide-formoterol between January 1, 2007, and February 29, 2024. Exposures: Receipt of a once-daily fluticasone furoate–vilanterol dry powder inhaler (Breo Ellipta; GSK), twice-daily fluticasone propionate–salmeterol dry powder inhaler (Advair Diskus; GSK), or twice-daily budesonide-formoterol metered-dose inhaler (Symbicort; AstraZeneca). Main Outcomes and Measures: The primary outcomes were first moderate or severe COPD exacerbation and first pneumonia hospitalization. Hazard ratios and 95% CIs were estimated using Cox proportional hazards regression models. Results: The cohorts included 38 070 matched pairs of patients receiving fluticasone furoate–vilanterol vs budesonide-formoterol (58.8% women; mean [SD] age, 71.0 [9.0] years), 20 471 matched pairs of patients receiving fluticasone furoate–vilanterol vs fluticasone propionate–salmeterol (58.3% women; mean [SD] age, 69.9 [9.2] years), and 55 627 matched pairs of patients receiving fluticasone propionate–salmeterol vs budesonide-formoterol (56.2% women; mean [SD] age, 68.3 [9.0] years). Patients receiving fluticasone furoate–vilanterol had a 9% lower risk of moderate or severe COPD exacerbations compared with those receiving budesonide-formoterol (hazard ratio [HR], 0.91 [95% CI, 0.88-0.94]; number needed to treat [NNT] = 40) and a 6% lower risk compared with those receiving fluticasone propionate–salmeterol (HR, 0.94 [95% CI, 0.89-0.98]; NNT = 40). The risk of moderate or severe COPD exacerbation was similar for patients receiving fluticasone propionate–salmeterol and budesonide-formoterol (HR, 0.98 [95% CI, 0.95-1.01]). No differences were observed in the risk of pneumonia hospitalization across the 3 cohorts (fluticasone furoate–vilanterol vs budesonide-formoterol: HR, 1.03 [95% CI, 0.96-1.11]; fluticasone furoate–vilanterol vs fluticasone propionate–salmeterol: HR, 0.93 [95% CI, 0.85-1.03]; and fluticasone propionate–salmeterol vs budesonide-formoterol: HR, 1.04 [95% CI, 0.98-1.10]). Conclusions and Relevance: In this cohort study of new ICS-LABA users with COPD, once-daily dry powder fluticasone furoate–vilanterol inhalers were associated with slightly improved clinical outcomes compared with twice-daily metered-dose budesonide-formoterol inhalers and twice-daily dry powder fluticasone propionate–salmeterol inhalers. Further studies are needed to explore potential intraclass differences among inhalers used to treat COPD.
- 2 March 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (3) , e260959
Open AccessFluticasone- vs Budesonide-Based Dual Therapy for COPD
Importance: Inhaled corticosteroid (ICS)–long-acting β-agonist (LABA) inhalers are generally considered therapeutically equivalent when treating chronic obstructive pulmonary disease (COPD). However, metered-dose inhalers in the class are associated with substantially higher greenhouse gas emissions than dry powder formulations, and studies have raised questions about potential intraclass differences in clinical outcomes among patients receiving ICS-LABAs. Objective: To analyze COPD exacerbations and pneumonia hospitalizations associated with once-daily fluticasone furoate–vilanterol dry powder inhalers, twice-daily fluticasone propionate–salmeterol dry powder inhalers, and twice-daily budesonide-formoterol metered-dose inhalers in adults with COPD. Design, Setting, and Participants: This cohort study was conducted using longitudinal commercial claims data of US adults aged 40 years or older with COPD. Patients were 1:1 pairwise propensity score matched into 3 cohorts: (1) new users receiving fluticasone furoate–vilanterol vs budesonide-formoterol between January 1, 2014, and February 29, 2024; (2) new users receiving fluticasone furoate–vilanterol vs fluticasone propionate–salmeterol between January 1, 2014, and February 29, 2024; and (3) new users receiving fluticasone propionate–salmeterol vs budesonide-formoterol between January 1, 2007, and February 29, 2024. Exposures: Receipt of a once-daily fluticasone furoate–vilanterol dry powder inhaler (Breo Ellipta; GSK), twice-daily fluticasone propionate–salmeterol dry powder inhaler (Advair Diskus; GSK), or twice-daily budesonide-formoterol metered-dose inhaler (Symbicort; AstraZeneca). Main Outcomes and Measures: The primary outcomes were first moderate or severe COPD exacerbation and first pneumonia hospitalization. Hazard ratios and 95% CIs were estimated using Cox proportional hazards regression models. Results: The cohorts included 38 070 matched pairs of patients receiving fluticasone furoate–vilanterol vs budesonide-formoterol (58.8% women; mean [SD] age, 71.0 [9.0] years), 20 471 matched pairs of patients receiving fluticasone furoate–vilanterol vs fluticasone propionate–salmeterol (58.3% women; mean [SD] age, 69.9 [9.2] years), and 55 627 matched pairs of patients receiving fluticasone propionate–salmeterol vs budesonide-formoterol (56.2% women; mean [SD] age, 68.3 [9.0] years). Patients receiving fluticasone furoate–vilanterol had a 9% lower risk of moderate or severe COPD exacerbations compared with those receiving budesonide-formoterol (hazard ratio [HR], 0.91 [95% CI, 0.88-0.94]; number needed to treat [NNT] = 40) and a 6% lower risk compared with those receiving fluticasone propionate–salmeterol (HR, 0.94 [95% CI, 0.89-0.98]; NNT = 40). The risk of moderate or severe COPD exacerbation was similar for patients receiving fluticasone propionate–salmeterol and budesonide-formoterol (HR, 0.98 [95% CI, 0.95-1.01]). No differences were observed in the risk of pneumonia hospitalization across the 3 cohorts (fluticasone furoate–vilanterol vs budesonide-formoterol: HR, 1.03 [95% CI, 0.96-1.11]; fluticasone furoate–vilanterol vs fluticasone propionate–salmeterol: HR, 0.93 [95% CI, 0.85-1.03]; and fluticasone propionate–salmeterol vs budesonide-formoterol: HR, 1.04 [95% CI, 0.98-1.10]). Conclusions and Relevance: In this cohort study of new ICS-LABA users with COPD, once-daily dry powder fluticasone furoate–vilanterol inhalers were associated with slightly improved clinical outcomes compared with twice-daily metered-dose budesonide-formoterol inhalers and twice-daily dry powder fluticasone propionate–salmeterol inhalers. Further studies are needed to explore potential intraclass differences among inhalers used to treat COPD.
- 1 March 2026
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 45 (3) , 322-330
List Price Reductions Among Brand-Name ICS-LABA Inhalers In 2024 Were Associated With Increased Generic Uptake
Inhaled corticosteroid-long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; however, the use of brand-name versions has remained high in the US even though generic versions have been marketed since 2017. Effective in January 2024, the American Rescue Plan Act of 2021 imposed new penalties for prior list price increases in Medicaid, prompting manufacturers of some ICS-LABAs to reduce list prices for these drugs. In an interrupted time series analysis, we used US nationwide prescription dispensing data to assess changes in generic uptake of ICS-LABAs after the brand-name list price reductions. Use of generic ICS-LABAs increased by 23 percentage points at the start of 2024, driven by changes in commercial plans (33 percentage points) and Medicare (24 percentage points). List price reductions may have limited the capacity for brand-name firms to offer large rebates to pharmacy benefit managers, blunting existing financial incentives that had favored brand-name over generic ICS-LABAs. These findings demonstrate how changes in list prices can promote generic competition and improve affordability for patients and payers.
- 1 March 2026
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 45 (3) , 322-330
List Price Reductions Among Brand-Name ICS-LABA Inhalers In 2024 Were Associated With Increased Generic Uptake
Inhaled corticosteroid-long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; however, the use of brand-name versions has remained high in the US even though generic versions have been marketed since 2017. Effective in January 2024, the American Rescue Plan Act of 2021 imposed new penalties for prior list price increases in Medicaid, prompting manufacturers of some ICS-LABAs to reduce list prices for these drugs. In an interrupted time series analysis, we used US nationwide prescription dispensing data to assess changes in generic uptake of ICS-LABAs after the brand-name list price reductions. Use of generic ICS-LABAs increased by 23 percentage points at the start of 2024, driven by changes in commercial plans (33 percentage points) and Medicare (24 percentage points). List price reductions may have limited the capacity for brand-name firms to offer large rebates to pharmacy benefit managers, blunting existing financial incentives that had favored brand-name over generic ICS-LABAs. These findings demonstrate how changes in list prices can promote generic competition and improve affordability for patients and payers.
- 1 March 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (3) , 440-441
The Pharmaceutical Industry’s Quiet Win in the One Big Beautiful Bill Act
- 1 March 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (3) , 440-441
The Pharmaceutical Industry’s Quiet Win in the One Big Beautiful Bill Act
- Open Access
- 19 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (7)
Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins
BACKGROUND: We constructed multi-trait polygenic risk scores (PRSs) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validated their performance in diverse cohorts, and identified PRS-related proteins for potential therapeutic targeting. METHODS: PRSmix + , a multi-trait PRS framework, is used to train a composite PRS (PRS multi ) in COPDGene non-Hispanic White participants ( n = 6,647). Associations of PRS multi with COPD status (GOLD 2–4 vs. GOLD 0 or ICD) and exacerbation frequency were tested in COPDGene African American ( n = 2,466), ECLIPSE ( n = 1,858), Mass General Brigham Biobank ( n = 15,152), and All of Us ( n = 118,566). Protein prediction models were applied to GWAS summary statistics from traits contributing to PRS multi and were validated with proteomic data in COPDGene ( n = 5,173) and UK Biobank ( n = 5,012). RESULTS: PRSmix + selected 7 traits for PRS multi . In multivariable models, PRS multi was associated with COPD status (meta-analysis random effects [RE] OR 1.58 [95% CI: 1.28–1.94]) and exacerbation frequency (meta-analysis RE β 0.21 [95% CI: 0.11–0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRS multi outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRSs that were also validated with measured protein levels in COPDGene and UK Biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include RAGE/sRAGE, IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. CONCLUSIONS: Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. TRIAL REGISTRATION: COPDGene: ClinicalTrials.gov NCT00608764; ECLIPSE: ClinicalTrials.gov NCT00292552.
- 19 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (7)
Open AccessMulti-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins
BACKGROUND: We constructed multi-trait polygenic risk scores (PRSs) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validated their performance in diverse cohorts, and identified PRS-related proteins for potential therapeutic targeting. METHODS: PRSmix + , a multi-trait PRS framework, is used to train a composite PRS (PRS multi ) in COPDGene non-Hispanic White participants ( n = 6,647). Associations of PRS multi with COPD status (GOLD 2–4 vs. GOLD 0 or ICD) and exacerbation frequency were tested in COPDGene African American ( n = 2,466), ECLIPSE ( n = 1,858), Mass General Brigham Biobank ( n = 15,152), and All of Us ( n = 118,566). Protein prediction models were applied to GWAS summary statistics from traits contributing to PRS multi and were validated with proteomic data in COPDGene ( n = 5,173) and UK Biobank ( n = 5,012). RESULTS: PRSmix + selected 7 traits for PRS multi . In multivariable models, PRS multi was associated with COPD status (meta-analysis random effects [RE] OR 1.58 [95% CI: 1.28–1.94]) and exacerbation frequency (meta-analysis RE β 0.21 [95% CI: 0.11–0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRS multi outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRSs that were also validated with measured protein levels in COPDGene and UK Biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include RAGE/sRAGE, IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. CONCLUSIONS: Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. TRIAL REGISTRATION: COPDGene: ClinicalTrials.gov NCT00608764; ECLIPSE: ClinicalTrials.gov NCT00292552.
- Open Access
- 2 January 2026
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 7 (1) , e255909
Tertiary Patents on Drugs Approved by the FDA
Importance: Manufacturers of drug-device combinations, such as inhalers and injectable medications, often obtain patents not just on the active pharmaceutical ingredients of these products (primary patents) but also on other features, such as their formulations and methods of use (secondary patents) and delivery devices (tertiary patents). Courts, policymakers, and regulators have recently begun scrutinizing whether manufacturers may be improperly listing tertiary patents with the Food and Drug Administration (FDA) that lack claims on active pharmaceutical ingredients and whether such patents may be delaying generic competition. However, the full scope of patenting practices on drug-device combinations remains unknown. Objective: To analyze patent protection on small-molecule drugs approved by the FDA from 1986 to 2023 with 1 or more tertiary patents. Design, Setting, and Participants: In this retrospective cohort study of patenting practices on drug-device combinations, all patents listed in the FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book) were categorized (primary, secondary, or tertiary), and products with at least 1 tertiary patent were included. Analyses were performed between May 2024 and October 2025. Main Outcomes and Measures: The primary outcome of the study was the duration of expected patent protection on each product, measured from the time of approval until expiration of the last-to-expire patent. Added protection from tertiary patents that went beyond protection afforded by primary or secondary patents was also analyzed. Results: The FDA approved 331 products from 1986 to 2023 with 1 or more tertiary patents; 137 of 3241 patents (4.2%) listed on these products were primary patents, 1353 of 3241 were secondary patents (41.7%), and 1751 of 3241 were tertiary patents (54.0%). Among tertiary patents, 1047 of 1751 (59.8%) lacked claims making any mention of active pharmaceutical ingredients. The median (IQR) duration of expected patent protection among products in the cohort was 17.6 (14.4-21.2) years. There were 180 products (54.4%) that had tertiary patents extending periods of expected protection beyond other patents, and the median (IQR) duration of added protection was 7.5 (2.8-13.9) years. Conclusions and Relevance: The findings of this cohort study suggest that policymakers and regulators should take steps to ensure that tertiary patents are not improperly listed in the Orange Book and that generic competition occurs in a timely fashion.
- 2 January 2026
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 7 (1) , e255909
Open AccessTertiary Patents on Drugs Approved by the FDA
Importance: Manufacturers of drug-device combinations, such as inhalers and injectable medications, often obtain patents not just on the active pharmaceutical ingredients of these products (primary patents) but also on other features, such as their formulations and methods of use (secondary patents) and delivery devices (tertiary patents). Courts, policymakers, and regulators have recently begun scrutinizing whether manufacturers may be improperly listing tertiary patents with the Food and Drug Administration (FDA) that lack claims on active pharmaceutical ingredients and whether such patents may be delaying generic competition. However, the full scope of patenting practices on drug-device combinations remains unknown. Objective: To analyze patent protection on small-molecule drugs approved by the FDA from 1986 to 2023 with 1 or more tertiary patents. Design, Setting, and Participants: In this retrospective cohort study of patenting practices on drug-device combinations, all patents listed in the FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book) were categorized (primary, secondary, or tertiary), and products with at least 1 tertiary patent were included. Analyses were performed between May 2024 and October 2025. Main Outcomes and Measures: The primary outcome of the study was the duration of expected patent protection on each product, measured from the time of approval until expiration of the last-to-expire patent. Added protection from tertiary patents that went beyond protection afforded by primary or secondary patents was also analyzed. Results: The FDA approved 331 products from 1986 to 2023 with 1 or more tertiary patents; 137 of 3241 patents (4.2%) listed on these products were primary patents, 1353 of 3241 were secondary patents (41.7%), and 1751 of 3241 were tertiary patents (54.0%). Among tertiary patents, 1047 of 1751 (59.8%) lacked claims making any mention of active pharmaceutical ingredients. The median (IQR) duration of expected patent protection among products in the cohort was 17.6 (14.4-21.2) years. There were 180 products (54.4%) that had tertiary patents extending periods of expected protection beyond other patents, and the median (IQR) duration of added protection was 7.5 (2.8-13.9) years. Conclusions and Relevance: The findings of this cohort study suggest that policymakers and regulators should take steps to ensure that tertiary patents are not improperly listed in the Orange Book and that generic competition occurs in a timely fashion.
- Open Access
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Physician Antibiotic Prescribing Preferences in Community Acquired Pneumonia and Complicated Urinary Tract Infections: A National Discrete Choice Experiment
Background: Physicians prescribing antibiotics for common infections must weigh trade-offs across drug attributes such as efficacy, dosing, side effects, and resistance. Understanding these priorities can help inform drug development, regulatory decisions, and insurance coverage determinations. Methods: We conducted a discrete choice experiment between June 5 and 9 July 2024, among a national sample of US physicians who prescribed antibiotics for community-acquired pneumonia (CAP) or complicated urinary tract infections (UTIs) in the past year. Respondents evaluated paired hypothetical antibiotics varying by 5 attributes: time to symptom improvement, dosing frequency, risk of nonserious and serious side effects, and risk of future resistance to the patient. Preference weights and relative importance scores were estimated using conditional logistic models. Subgroup analyses were conducted by disease, care setting, and specialty. Results: Of 880 enrolled physicians, 756 (86%) completed the survey. Respondents had a mean age of 51.5 years; 60% were male, and most practiced general internal medicine (64%) or infectious disease (15%). The most influential attributes overall were symptom improvement (relative importance score: 28%) and dosing convenience (relative importance score: 27%). In inpatient settings, physicians prioritized symptom improvement (relative importance score: 33%), while outpatient physicians prioritized dosing frequency (relative importance score: 31%). Risk of future antibiotic resistance to the patient was consistently the least influential attribute (relative importance score: 7%–13%) across disease-types and clinical settings. Conclusions: In this national survey study, physicians prioritized rapid symptom relief and dosing convenience over other drug attributes when prescribing antibiotics for CAP and UTIs. Understanding physician priorities can help inform stewardship strategies and clinician-facing decision support, and encourage regulators and sponsors to prioritize clinically meaningful trial endpoints.
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessPhysician Antibiotic Prescribing Preferences in Community Acquired Pneumonia and Complicated Urinary Tract Infections: A National Discrete Choice Experiment
Background: Physicians prescribing antibiotics for common infections must weigh trade-offs across drug attributes such as efficacy, dosing, side effects, and resistance. Understanding these priorities can help inform drug development, regulatory decisions, and insurance coverage determinations. Methods: We conducted a discrete choice experiment between June 5 and 9 July 2024, among a national sample of US physicians who prescribed antibiotics for community-acquired pneumonia (CAP) or complicated urinary tract infections (UTIs) in the past year. Respondents evaluated paired hypothetical antibiotics varying by 5 attributes: time to symptom improvement, dosing frequency, risk of nonserious and serious side effects, and risk of future resistance to the patient. Preference weights and relative importance scores were estimated using conditional logistic models. Subgroup analyses were conducted by disease, care setting, and specialty. Results: Of 880 enrolled physicians, 756 (86%) completed the survey. Respondents had a mean age of 51.5 years; 60% were male, and most practiced general internal medicine (64%) or infectious disease (15%). The most influential attributes overall were symptom improvement (relative importance score: 28%) and dosing convenience (relative importance score: 27%). In inpatient settings, physicians prioritized symptom improvement (relative importance score: 33%), while outpatient physicians prioritized dosing frequency (relative importance score: 31%). Risk of future antibiotic resistance to the patient was consistently the least influential attribute (relative importance score: 7%–13%) across disease-types and clinical settings. Conclusions: In this national survey study, physicians prioritized rapid symptom relief and dosing convenience over other drug attributes when prescribing antibiotics for CAP and UTIs. Understanding physician priorities can help inform stewardship strategies and clinician-facing decision support, and encourage regulators and sponsors to prioritize clinically meaningful trial endpoints.